Related references
Note: Only part of the references are listed.The Range of Human APOBEC3H Sensitivity to Lentiviral Vif Proteins
Melody M. H. Li et al.
JOURNAL OF VIROLOGY (2010)
The current structural and functional understanding of APOBEC deaminases
Ronda Bransteitter et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2009)
Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G
Ayako Furukawa et al.
EMBO JOURNAL (2009)
Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1
Lindi Tan et al.
FASEB JOURNAL (2009)
Inhibition of HIV-1 Infection and Replication by Enhancing Viral Incorporation of Innate Anti-HIV-1 Protein A3G A NON-PATHOGENIC Nef MUTANT-BASED ANTI-HIV STRATEGY
Linden A. Green et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Microarray Analysis of Lymphatic Tissue Reveals Stage-Specific, Gene Expression Signatures in HIV-1 Infection
Qingsheng Li et al.
JOURNAL OF IMMUNOLOGY (2009)
APOBEC3B Deletion and Risk of HIV-1 Acquisition
Ping An et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
An Extended Structure of the APOBEC3G Catalytic Domain Suggests a Unique Holoenzyme Model
Elena Harjes et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
Regulation of APOBEC3 Proteins by a Novel YXXL Motif in Human Immunodeficiency Virus Type 1 Vif and Simian Immunodeficiency Virus SIVagm Vif
Erez Pery et al.
JOURNAL OF VIROLOGY (2009)
Distinct Domains within APOBEC3G and APOBEC3F Interact with Separate Regions of Human Immunodeficiency Virus Type 1 Vif
Rebecca A. Russell et al.
JOURNAL OF VIROLOGY (2009)
Polymorphisms and Splice Variants Influence the Antiretroviral Activity of Human APOBEC3H
Ariana Harari et al.
JOURNAL OF VIROLOGY (2009)
A Patch of Positively Charged Amino Acids Surrounding the Human Immunodeficiency Virus Type 1 Vif SLVx4Yx9Y Motif Influences Its Interaction with APOBEC3G
Gongying Chen et al.
JOURNAL OF VIROLOGY (2009)
Analysis of the Percentage of Human Immunodeficiency Virus Type 1 Sequences That Are Hypermutated and Markers of Disease Progression in a Longitudinal Cohort, Including One Individual with a Partially Defective Vif
Anne Piantadosi et al.
JOURNAL OF VIROLOGY (2009)
Identification of a Novel WxSLVK Motif in the N Terminus of Human Immunodeficiency Virus and Simian Immunodeficiency Virus Vif That Is Critical for APOBEC3G and APOBEC3F Neutralization
Ying Dang et al.
JOURNAL OF VIROLOGY (2009)
Defining APOBEC3 Expression Patterns in Human Tissues and Hematopoietic Cell Subsets
Fransje A. Koning et al.
JOURNAL OF VIROLOGY (2009)
Architecture and secondary structure of an entire HIV-1 RNA genome
Joseph M. Watts et al.
NATURE (2009)
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells
Ronald T. Mitsuyasu et al.
NATURE MEDICINE (2009)
Tumultuous Relationship between the Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) and the Human APOBEC-3G and APOBEC-3F Restriction Factors
Simon Henriet et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2009)
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantaion
Gero Huetter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
APOBEC3G-Depleted Resting CD4+ T Cells Remain Refractory to HIV1
Francesca R. Santoni de Sio et al.
PLOS ONE (2009)
APOBEC proteins and intrinsic resistance to HIV-1 infection
Michael H. Malim
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2009)
APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression
Joel A. Vazquez-Perez et al.
RETROVIROLOGY (2009)
Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development
Jessica L. Smith et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent
Edward P. Browne et al.
VIROLOGY (2009)
Reassessing the Role of APOBEC3G in Human Immunodeficiency Virus Type 1 Infection of Quiescent CD4+T-Cells
Masakazu Kamata et al.
PLOS PATHOGENS (2009)
Differences in APOBEC3G Expression in CD4+T Helper Lymphocyte Subtypes Modulate HIV-1 Infectivity
Michael L. Vetter et al.
PLOS PATHOGENS (2009)
RNA-Dependent Oligomerization of APOBEC3G Is Required for Restriction of HIV-1
Hendrik Huthoff et al.
PLOS PATHOGENS (2009)
Likely Role of APOBEC3G-Mediated G-to-A Mutations in HIV-1 Evolution and Drug Resistance
Patric Jern et al.
PLOS PATHOGENS (2009)
HIV Evolution in Early Infection: Selection Pressures, Patterns of Insertion and Deletion, and the Impact of APOBEC
Natasha Wood et al.
PLOS PATHOGENS (2009)
Accessories to the crime: Recent advances in HIV accessory protein biology
Thomas Gramberg et al.
Current HIV/AIDS Reports (2009)
The Level of APOBEC3G (hA3G)-Related G-to-A Mutations Does Not Correlate with Viral Load in HIV Type 1-Infected Individuals
Nzovu K. Ulenga et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2008)
The APOBEC3 cytidine deaminases: An innate defensive network opposing exogenous retroviruses and endogenous retroelements
Ya-Lin Chiu et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
HIV-1 accessory proteins - Ensuring viral survival in a hostile environment
Michael H. Malim et al.
CELL HOST & MICROBE (2008)
Antiretroelement activity of APOBEC3H was lost twice in recent human evolution
Molly OhAinle et al.
CELL HOST & MICROBE (2008)
Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G
Guylaine Hache et al.
CURRENT BIOLOGY (2008)
Hepatitis B: modern concepts in pathogenesis - APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus
Marianne Bonvin et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2008)
Human cytidine deaminase APOBEC3H restricts HIV-1 replication
Ying Dang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F
Nzovu K. Ulenga et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction
Zhiwen He et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya
Allison M. Land et al.
JOURNAL OF VIROLOGY (2008)
Equine Infectious Anemia Virus Resists the Antiretroviral Activity of Equine APOBEC3 Proteins through a Packaging-Independent Mechanism
Hal P. Bogerd et al.
JOURNAL OF VIROLOGY (2008)
The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction
April J. Schumacher et al.
JOURNAL OF VIROLOGY (2008)
Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications
Lauren G. Holden et al.
NATURE (2008)
Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G
Kuan-Ming Chen et al.
NATURE (2008)
Small-molecule inhibition of HIV-1 Vif
Robin Nathans et al.
NATURE BIOTECHNOLOGY (2008)
Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F
Tomoki Yamashita et al.
MICROBES AND INFECTION (2008)
Vpr14-88-Apobec3G Fusion Protein Is Efficiently Incorporated into Vif-Positive HIV-1 Particles and Inhibits Viral Infection
Zhujun Ao et al.
PLOS ONE (2008)
Distinct Determinants in HIV-1 Vif and Human APOBEC3 Proteins Are Required for the Suppression of Diverse Host Anti-Viral Proteins
Wenyan Zhang et al.
PLOS ONE (2008)
Cytidine deamination induced HIV-1 drug resistance
Lubbertus C. F. Mulder et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
APOBEC3G-UBA2 fusion as a potential strategy for stable expression of APOBEC3G and inhibition of HIV-1 replication
Lin Li et al.
RETROVIROLOGY (2008)
Turning up the volume on mutational pressure: Is more of a good thing always better? (A case study of HIV-I Vif and APOBEC3)
Satish K. Pillai et al.
RETROVIROLOGY (2008)
HIV-I Vif, APOBEC, and intrinsic immunity
Ritu Goila-Gaur et al.
RETROVIROLOGY (2008)
Functional domain organization of human APOBEOG
Barry D. Gooch et al.
VIROLOGY (2008)
Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation
Li Zhang et al.
VIROLOGY (2008)
APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication
Yanxing Han et al.
PLOS PATHOGENS (2008)
APOBEC3G Inhibits Elongation of HIV-1 Reverse Transcripts
Kate N. Bishop et al.
PLOS PATHOGENS (2008)
Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors
Shiv K. Gandhi et al.
JOURNAL OF VIROLOGY (2008)
Vpr.A3A chimera inhibits HIV replication
Renato S. Aguiar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism
Mariana Marin et al.
JOURNAL OF VIROLOGY (2008)
Genetic therapies against HIV
John J. Rossi et al.
NATURE BIOTECHNOLOGY (2007)
Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1
Eri Miyagij et al.
JOURNAL OF VIROLOGY (2007)
Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G
Yasumasa Iwatani et al.
NUCLEIC ACIDS RESEARCH (2007)
APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription
Xiao-Yu Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity
Ritu Goila-Gaur et al.
RETROVIROLOGY (2007)
Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F
Yiliang Yang et al.
VIROLOGY (2007)
The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains
Hal P. Bogerd et al.
VIROLOGY (2007)
Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F
Rebecca A. Russell et al.
JOURNAL OF VIROLOGY (2007)
Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression
Gang Peng et al.
BLOOD (2007)
Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration
Jean L. Mbisa et al.
JOURNAL OF VIROLOGY (2007)
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation
Kun Luo et al.
JOURNAL OF VIROLOGY (2007)
All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition
Masanobu Kinomoto et al.
NUCLEIC ACIDS RESEARCH (2007)
Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA
Bin Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: A possible role in the resistance to HIV of HIV-exposed seronegative individuals
Mara Biasin et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and virion encapsidation
Hendrik Huthoff et al.
JOURNAL OF VIROLOGY (2007)
Population stratification of a common APOBEC gene deletion polymorphism
Jeffrey M. Kidd et al.
PLOS GENETICS (2007)
APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation - Comparisons with APOBEC3G
Rebecca K. Holmes et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The APOBEC-2 crystal structure and functional implications for the deaminase AID
Courtney Prochnow et al.
NATURE (2007)
APOBEC-mediated viral restriction: not simply editing?
Rebecca K. Holmes et al.
TRENDS IN BIOCHEMICAL SCIENCES (2007)
APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection
Marjorie Pion et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Inhibition of tRNALys3-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replicationv
Fei Guo et al.
JOURNAL OF VIROLOGY (2006)
Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains
Yoshiyuki Hakata et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family
Ying Dang et al.
JOURNAL OF VIROLOGY (2006)
APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians
Han Sang Valcke et al.
AIDS (2006)
Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation
Craig Pace et al.
JOURNAL OF VIROLOGY (2006)
Antiviral potency of APOBEC proteins does not correlate with cytidine deamination
Kate N. Bishop et al.
JOURNAL OF VIROLOGY (2006)
APOBEC3 proteins inhibit human LINE-1 retrotransposition
Heide Muckenfuss et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Alpha interferon potently enhances the anti-human immunodeficiency virus type I activity of APOBEC3G in resting primary CD4 T cells
Keyang Chen et al.
JOURNAL OF VIROLOGY (2006)
APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism
Mark D. Stenglein et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Cellular inhibitors of long interspersed element 1 and Alu retrotransposition
Hal P. Bogerd et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H
M OhAinle et al.
JOURNAL OF VIROLOGY (2006)
APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons
H Chen et al.
CURRENT BIOLOGY (2006)
Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F
CJ Tian et al.
JOURNAL OF VIROLOGY (2006)
APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count
SJ Cho et al.
JOURNAL OF VIROLOGY (2006)
Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity
G Peng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G
SM Kaiser et al.
JOURNAL OF VIROLOGY (2006)
APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells
HP Bogerd et al.
NUCLEIC ACIDS RESEARCH (2006)
Natural variation in Vif: Differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification
Viviana Simon et al.
PLOS PATHOGENS (2005)
APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia
X Jin et al.
JOURNAL OF VIROLOGY (2005)
Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases
B Schröfelbauer et al.
JOURNAL OF VIROLOGY (2005)
Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif
BP Doehle et al.
VIROLOGY (2005)
APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast
AJ Schumacher et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G
KM Rose et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2005)
被撤回的出版物: Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells (Retracted Article. See vol 466, pg 276, 2010)
YL Chiu et al.
NATURE (2005)
HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation
M Santa-Marta et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
HIV-1-associated uracil DNA glycosylase activity controls dUTP misincorporation in viral DNA and is essential to the HIV-1 life cycle
S Priet et al.
MOLECULAR CELL (2005)
G→A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo
TL Kieffer et al.
JOURNAL OF VIROLOGY (2005)
Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases
SG Conticello et al.
MOLECULAR BIOLOGY AND EVOLUTION (2005)
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity
ENC Newman et al.
CURRENT BIOLOGY (2005)
Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort
H Do et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities
MA Langlois et al.
NUCLEIC ACIDS RESEARCH (2005)
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion
HZ Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to vif action
B Mangeat et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Inhibition of hepatitis B virus replication by APOBEC3G
P Turelli et al.
SCIENCE (2004)
A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor
HP Bogerd et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif)
R Schröfelbauer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway
A Mehle et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
APOBEC3G genetic variants and their influence on the progression to AIDS
P An et al.
JOURNAL OF VIROLOGY (2004)
APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations
B Berkhout et al.
AIDS (2004)
Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G
SL Sawyer et al.
PLOS BIOLOGY (2004)
Cytidine deamination of retroviral DNA by diverse APOBEC proteins
KN Bishop et al.
CURRENT BIOLOGY (2004)
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo
MT Liddament et al.
CURRENT BIOLOGY (2004)
APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication
Q Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines
YK Yu et al.
GENES & DEVELOPMENT (2004)
Vpr-mediated incorporation of UNG2 into HIV-1 particles is required to modulate the virus mutation rate and for replication in macrophages
RX Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation
A Mehle et al.
GENES & DEVELOPMENT (2004)
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins
HL Wiegand et al.
EMBO JOURNAL (2004)
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication
YH Zheng et al.
JOURNAL OF VIROLOGY (2004)
Retroviral restriction by APOBEC proteins
RS Harris et al.
NATURE REVIEWS IMMUNOLOGY (2004)
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome
Q Yu et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2004)
The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G
SG Conticello et al.
CURRENT BIOLOGY (2003)
The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity
K Shindo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex
XH Yu et al.
SCIENCE (2003)
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability
K Stopak et al.
MOLECULAR CELL (2003)
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif
R Mariani et al.
CELL (2003)
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts
B Mangeat et al.
NATURE (2003)
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA
H Zhang et al.
NATURE (2003)
DNA determination mediates innate immunity to retroviral infection
RS Harris et al.
CELL (2003)
Hypermutation of HIV-1 DNA in the absence of the Vif protein
D Lecossier et al.
SCIENCE (2003)
Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business
JE Wedekind et al.
TRENDS IN GENETICS (2003)
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif
AM Sheehy et al.
NATURE MEDICINE (2003)
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation
M Marin et al.
NATURE MEDICINE (2003)
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity
S Kao et al.
JOURNAL OF VIROLOGY (2003)
RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators
RS Harris et al.
MOLECULAR CELL (2002)
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein
AM Sheehy et al.
NATURE (2002)
AID mutates E-coli suggesting a DNA deamination mechanism for antibody diversification
SK Petersen-Mahrt et al.
NATURE (2002)
An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22
A Jarmuz et al.
GENOMICS (2002)
Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4+ T cells
M Janini et al.
JOURNAL OF VIROLOGY (2001)
The interaction of Vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 in vivo mutation rate
LM Mansky et al.
JOURNAL OF VIROLOGY (2000)